NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia Co-Founder Prof. Dr. Laura vanโt Veer Honored at Three Prestigious Breast Cancer Symposia in Italy, the Netherlands and the U.S. for Pioneering Work in Breast Cancer Diagnostics
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS, November 14, 2024 - Prof. Dr. Laura van 't Veer, co-founder of Agendia, pioneer in personalized cancer care and co-developer of the MammaPrintยฎ genomic breast cancer recurrence test, Read More
Agendia’s FLEX Study Reaches Enrollment of Over 17,000 Early-Stage Breast Cancer Patients Across Diverse Population
This achievement highlights the remarkable seven-year progression of FLEX and its many sub-studies highlighting the ethnic and racial nuances that may influence treatment pathways. IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ September 12, 2024 Read More
Agendia Achieves CE-IVDR Certification
Agendia Achieves CE-IVDR Certification for its MammaPrint and BluePrint Breast Cancer Assays
Read MoreNewsroom
News, Stories & Breast Cancer Blog
Faith Over Fear, My Life Matters (Winter 2023-2024)
A journey to inclusive breast cancer care through faith, science, and personalized testing.
Read the ArticleArticle: Disparities in Survival Outcomes Revealed w/ BluePrint + MammaPrint
โThese data highlight the importance of genomic testing to help optimize treatment and reduce outcome disparities in Black women.โ
Read the ArticleAgendia Touting New Data Showing Pre-Surgery Use of MammaPrint, BluePrint
Research showing that Agendia's MammaPrint and BluePrint tests can predict which breast cancer patients are likely to have the cancer in their lymph nodes down-staged following neoadjuvant chemotherapy has the company optimistic about a potentially new use for its gene expression tests.
Read the ArticleFierce Healthcare: Bidenโs โCancer Moonshotโ is already being fueled by tech addressing breast cancer
Fierce Healthcare recently spoke with Nathalie Johnson, MD, FACS, President of The American Society of Breast Cancer Surgeons, about the need for more widespread use of advanced gene expression profiling tests that provide more consistent results for Black women with early-stage breast cancer. Dr. Johnson highlights how the standard of care today negatively impacts outcomes for Black women, and why it is essential for clinicians to switch to more sophisticated, unbiased tests, such as MammaPrint & BluePrint, to address key disparities in breast cancer care.
Read the Article
